AR104296A1 - Infusión arterial hepática de células car-t - Google Patents

Infusión arterial hepática de células car-t

Info

Publication number
AR104296A1
AR104296A1 ARP160101045A ARP160101045A AR104296A1 AR 104296 A1 AR104296 A1 AR 104296A1 AR P160101045 A ARP160101045 A AR P160101045A AR P160101045 A ARP160101045 A AR P160101045A AR 104296 A1 AR104296 A1 AR 104296A1
Authority
AR
Argentina
Prior art keywords
car
cells
hepatic blood
blood infusion
methods include
Prior art date
Application number
ARP160101045A
Other languages
English (en)
Spanish (es)
Inventor
Junghans Richard
C Katz Steven
Original Assignee
Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57126310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center filed Critical Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center
Publication of AR104296A1 publication Critical patent/AR104296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP160101045A 2015-04-15 2016-04-15 Infusión arterial hepática de células car-t AR104296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562147793P 2015-04-15 2015-04-15

Publications (1)

Publication Number Publication Date
AR104296A1 true AR104296A1 (es) 2017-07-12

Family

ID=57126310

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101045A AR104296A1 (es) 2015-04-15 2016-04-15 Infusión arterial hepática de células car-t

Country Status (13)

Country Link
US (2) US10471098B2 (OSRAM)
EP (1) EP3283083A4 (OSRAM)
JP (1) JP2018513216A (OSRAM)
KR (1) KR20180021364A (OSRAM)
CN (1) CN108135937A (OSRAM)
AR (1) AR104296A1 (OSRAM)
AU (1) AU2016248090A1 (OSRAM)
CA (1) CA2982603A1 (OSRAM)
HK (1) HK1251179A1 (OSRAM)
IL (1) IL255005A0 (OSRAM)
MX (1) MX2017013247A (OSRAM)
TW (1) TWI719019B (OSRAM)
WO (1) WO2016168493A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2948135T3 (es) 2015-06-24 2023-08-31 Univ Michigan Regents Sistemas de terapia de histotripsia para el tratamiento del tejido cerebral
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
US20200215112A1 (en) * 2017-08-09 2020-07-09 Ctg Pharma Ltd. Chimeric antigen receptor for her2/neu and t-cells expressing same
CA3080109A1 (en) * 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
JP7355294B2 (ja) * 2017-11-30 2023-10-03 シンガポール ヘルス サービシズ ピーティーイー． リミテッド がん患者を適切ながん処置群に分類するためのシステム及び方法、並びに患者を処置するための化合物
AU2019231315A1 (en) * 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
SG11202101014XA (en) * 2018-08-02 2021-02-25 Kite Pharma Inc Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
US20210346430A9 (en) * 2018-08-26 2021-11-11 Oaiscell Biotechnologies Method for treating glioblastoma
JP7520818B2 (ja) * 2018-09-13 2024-07-23 ンカルタ・インコーポレイテッド 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
CN120324803A (zh) 2018-11-28 2025-07-18 希斯托索尼克斯公司 组织摧毁术系统及方法
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
MX2022006288A (es) * 2019-11-25 2022-06-08 Univ Kyoto Banco de celulas maestras de celulas t.
EP4096782A4 (en) * 2020-01-28 2024-02-14 The Regents Of The University Of Michigan SYSTEMS AND METHODS FOR HISTOTRIPSIA IMMUNOSENSITIZATION
AU2021332372A1 (en) 2020-08-27 2023-03-16 The Regents Of The University Of Michigan Ultrasound transducer with transmit-receive capability for histotripsy
CN116685330A (zh) * 2020-09-22 2023-09-01 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
US20230364125A1 (en) * 2020-09-22 2023-11-16 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
CA3204922A1 (en) * 2021-02-09 2022-08-18 Ming-Tain Lai Globo series antigens-binding chimeric antigen receptors and uses thereof
EP4608504A1 (en) 2022-10-28 2025-09-03 Histosonics, Inc. Histotripsy systems and methods
AU2024257180A1 (en) 2023-04-20 2025-09-18 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025144964A2 (en) * 2023-12-29 2025-07-03 AffyImmune Therapeutics Inc. Novel car constructs and methods of treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020165360A1 (en) * 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
WO2010085660A2 (en) 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
CN104853766A (zh) * 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy

Also Published As

Publication number Publication date
JP2018513216A (ja) 2018-05-24
EP3283083A1 (en) 2018-02-21
KR20180021364A (ko) 2018-03-02
US20160303166A1 (en) 2016-10-20
CN108135937A (zh) 2018-06-08
WO2016168493A1 (en) 2016-10-20
TWI719019B (zh) 2021-02-21
AU2016248090A1 (en) 2017-11-02
MX2017013247A (es) 2018-08-15
US10471098B2 (en) 2019-11-12
CA2982603A1 (en) 2016-10-20
TW201708542A (zh) 2017-03-01
US20200138863A1 (en) 2020-05-07
HK1251179A1 (zh) 2019-01-25
EP3283083A4 (en) 2018-10-31
IL255005A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
AR104296A1 (es) Infusión arterial hepática de células car-t
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
CL2017000515A1 (es) Cd123 agentes enlazadores y su uso
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
MX2018005229A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo.
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
NI201800027A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos.
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2017006408A (es) Linfocitos t gamma delta modificados geneticamente.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CR20180105A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
MX2016013863A (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos.
MX375838B (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas.
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
MX390931B (es) Inhibidores marcados con 18f mejorados del antígeno prostático específico de membrana (psma) y su uso como agentes de formación de imágenes para el cáncer de próstata.
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra

Legal Events

Date Code Title Description
FB Suspension of granting procedure